

Data Sharing Statement

Yotsuyanagi. Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19. *JAMA Netw Open*. Published February 09, 2024.

doi:10.1001/jamanetworkopen.2023.54991

Data

Data available: Yes

Data types: Deidentified participant data

How to access data: Shionogi & Co, Ltd, is committed to disclosing the synopses and results of its clinical trials and sharing the clinical trial data with researchers on reasonable request.

For further details, please refer to the websites of Shionogi & Co, Ltd

(<https://www.shionogi.com/shionogi/global/en/company/policies/shionogi-group-clinical-trial-data-transparency-policy.html>) and Vivli (<https://vivli.org/>).

When available: With publication

Supporting Documents

Document types: Informed consent form

How to access documents: I will respond to each request individually. Email address:

takeki.uehara@shionogi.co.jp

When available: With publication

Additional Information

Who can access the data: Researchers whose proposed use of the data has been approved

Types of analyses: For a specified purpose

Mechanisms of data availability: After approval of a proposal